S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Forecast, Price & News

$1.55
-0.05 (-3.13%)
(As of 05/26/2023 ET)
Compare
Today's Range
$1.51
$1.63
50-Day Range
$1.49
$1.95
52-Week Range
$1.22
$8.45
Volume
12,063 shs
Average Volume
22,091 shs
Market Capitalization
$49.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NBRV stock logo

About Nabriva Therapeutics (NASDAQ:NBRV) Stock

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

NBRV - Nabriva Therapeutics plc
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
NBRV Nabriva Therapeutics plc
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Nabriva Therapeutics Provides Corporate Update
Nabriva's stock is up after sharing antibiotic news
See More Headlines
Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Company Calendar

Last Earnings
4/17/2023
Today
5/28/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBRV
Employees
72
Year Founded
N/A

Profitability

Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%

Debt

Sales & Book Value

Annual Sales
$36.94 million
Book Value
($0.14) per share

Miscellaneous

Free Float
31,493,000
Market Cap
$49.62 million
Optionable
Optionable
Beta
1.56

Key Executives

  • John Christopher NaftzgerJohn Christopher Naftzger
    CEO, Secretary & General Counsel
  • Dan Dolan
    Chief Financial Officer
  • Kim Anderson
    Investor & Media Contact













NBRV Stock - Frequently Asked Questions

Should I buy or sell Nabriva Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" NBRV shares.
View NBRV analyst ratings
or view top-rated stocks.

How have NBRV shares performed in 2023?

Nabriva Therapeutics' stock was trading at $1.89 on January 1st, 2023. Since then, NBRV stock has decreased by 18.0% and is now trading at $1.55.
View the best growth stocks for 2023 here
.

When is Nabriva Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our NBRV earnings forecast
.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings results on Monday, April, 17th. The biotechnology company reported ($7.77) earnings per share for the quarter. The biotechnology company earned $10.57 million during the quarter. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%.

When did Nabriva Therapeutics' stock split?

Shares of Nabriva Therapeutics reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.55.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $49.62 million and generates $36.94 million in revenue each year. The biotechnology company earns $-57,190,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.

This page (NASDAQ:NBRV) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -